Nishino Takayoshi, Toki Fumitake, Oi Itaru, Oyama Hiroyasu, Hatori Takashi, Shiratori Keiko
Institute of Gastroenterology, Department of Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada, Shinjuku-ku, Tokyo 162-8666, Japan.
J Gastroenterol. 2006 Nov;41(11):1088-93. doi: 10.1007/s00535-006-1893-z. Epub 2006 Dec 8.
The present study was undertaken to evaluate the prevalence of pancreatic and biliary tract tumors in pancreas divisum (PD).
A retrospective single-center study was performed, and a total of 118 cases of complete PD and 7850 cases of fused pancreas were identified among the 8537 consecutive new endoscopic retrograde cholangiopancreatography (ERCP) examinations performed between 1980 and 2002. The prevalence of pancreatic cancer (PCA), intraductal papillary mucinous neoplasms (IPMNs), other pancreatic tumors, and biliary tract cancer in the patients with PD and the patients with a fused pancreas were compared.
The prevalence of the pancreatic tumors in the PD patients was: PCA, 10%; IPMN, 5.1%; other pancreatic tumors, 2.5%. The prevalence of pancreatic tumors in the patients with a fused pancreas was: PCA, 4.8%; IPMN, 2.6%; and other pancreatic tumors, 1.1%. The prevalence of PCA was significantly higher in the patients with PD than in those with a fused pancreas (P = 0.008; OR, 2.24). The percentages of PD patients with PCA who had pancreatic-type pain and a serum pancreatic enzyme elevation were significantly higher than among the PD patients without PCA. The prevalence of biliary tract cancer was 0.8% in the PD group and 5.3% in the fused pancreas group, and it was significantly lower in PD than in fused pancreas (P = 0.031).
The results of this study showed a significantly higher prevalence of PCA in PD than in fused pancreas. We concluded that patients with PD, especially patients presenting with pancreatic-type pain and pancreatic enzyme elevation, should be carefully followed up because of the risk of developing PCA.
本研究旨在评估胰腺分裂(PD)患者中胰腺和胆道肿瘤的患病率。
进行了一项回顾性单中心研究,在1980年至2002年间连续进行的8537例新的内镜逆行胰胆管造影(ERCP)检查中,共识别出118例完全性PD患者和7850例融合胰腺患者。比较了PD患者和融合胰腺患者中胰腺癌(PCA)、导管内乳头状黏液性肿瘤(IPMN)、其他胰腺肿瘤和胆道癌的患病率。
PD患者中胰腺肿瘤的患病率为:PCA,10%;IPMN,5.1%;其他胰腺肿瘤,2.5%。融合胰腺患者中胰腺肿瘤的患病率为:PCA,4.8%;IPMN,2.6%;其他胰腺肿瘤,1.1%。PD患者中PCA的患病率显著高于融合胰腺患者(P = 0.008;OR,2.24)。有PCA的PD患者出现胰腺型疼痛和血清胰酶升高的百分比显著高于无PCA的PD患者。PD组胆道癌的患病率为0.8%,融合胰腺组为5.3%,PD组显著低于融合胰腺组(P = 0.031)。
本研究结果显示,PD患者中PCA的患病率显著高于融合胰腺患者。我们得出结论,由于存在发生PCA的风险,PD患者,尤其是出现胰腺型疼痛和胰酶升高的患者,应进行密切随访。